| Objective:1.To evaluate the efficacy and safety of anti-CD19/CD22 chimeric antigen receptor T cell therapy in the treatment of relapsed and refractory acute B lymphoblastic leukemia;2.To evaluate the role of JAK inhibitors in the treatment of CAR-T cell-related CRS.Method:A retrospective analysis was conducted to evaluate the efficacy and safety of anti-CD19/CD22 CAR-T cell therapy in the Department of Hematology,Second Affiliated Hospital of Nanchang University,from January 1,2019 to December 31,2021,to evaluate the efficacy and safety of anti-CD19/CD22 CAR-T therapy for relapsed and refractory acute B lymphoblastic leukemia.Results:1.8 patients achieved complete remission 28 days after receiving anti-CD19/CD22 CAR-T cell therapy,and up to now,6 patients who did not receive hematopoietic stem cell transplantation after CAR-T cell therapy had a median PFS of 5.5 months(2-48 months),and the OS efficacy was 48 months,and it was still in continuous remission.2.8 patients developed CRS after receiving anti-CD19/CD22 CAR-T cell therapy,the highest grade 3,the lowest grade 1,no neurotoxicity,no deaths.3.JAK inhibitor Ruxolitinib combined with glucocorticoids and tocilizumab can effectively control CAR-T cell-related CRS.Conclusion:1.The short-term efficacy of anti-CD19/CD22 CAR-T cells in the treatment of relapsed and refractory acute Blymphoblastic leukemia is certain;2.Anti-CD19/CD22 CAR-T cell therapy for relapsed and refractory acute Blymphoblastic leukemia is safe and controllable;3.JAK inhibitor Ruxolitinib may be a potential drug for the treatment of CAR-T cell-related CRS. |
